NCT05878184View on ClinicalTrials.gov

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

November 4, 2025

Study Completion Date

November 4, 2038

Conditions
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

SC291

SC291 is an allogeneic CAR-T cell therapy

Trial Locations (10)

3000

Peter MacCallum Cancer Centre, Melbourne

5000

Royal Adelaide Hospital, Adelaide

6009

Linear Clinical Research Ltd, Nedlands

30342

Northside Hospital, Atlanta

48201

Karmanos Cancer Institute, Detroit

66205

University of Kansas Medical Center, Fairway

68198

University of Nebraska Medical Center, Omaha

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

94304

Stanford Cancer Institute, Palo Alto

Sponsors

Lead Sponsor

Sana Biotechnology
All Listed Sponsors
lead

Sana Biotechnology

INDUSTRY

NCT05878184 - Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Biotech Hunter | Biotech Hunter